Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 7, 2007 - Issue 4
Submit an article Journal homepage
594
Views
9
CrossRef citations to date
0
Altmetric
Editorial

Viruses in the treatment of malignant glioma

Richard G Everson Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA. [email protected]
,
Mathias Gromeier Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA. [email protected]
&
John H Sampson Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA. [email protected]
Pages 321-324 | Published online: 09 Jan 2014

References

  • Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. Anticancer Drugs17(9), 1003–1016 (2006).
  • Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res.10(16), 5316–5326 (2004).
  • Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol.21(8), 1624–1636 (2003).
  • Dandy WE. Removal of right cerebral hemisphere for certain tumors with hemiplegia. JAMA90, 823–825 (1928).
  • Kuruppu D, Tanabe KK. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol. Ther.4(5), 524–531 (2005).
  • Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol.65(3), 203–226 (2003).
  • Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol. Ther.12(4), 585–598 (2005).
  • McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther.2(4 Suppl. 1), S157–S160 (2003).
  • Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol.65(3), 237–246 (2003).
  • Alemany R. Cancer selective adenoviruses. Mol. Aspects Med.28(1), 42–58 (2007).
  • Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol.2(1), 137–143 (2006).
  • Hedley SJ, Chen J, Mountz JD et al. Targeted and shielded adenovectors for cancer therapy. Cancer Immunol. Immunother.55(11), 1412–1419 (2006).
  • Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro-oncol.6(3), 208–217 (2004).
  • Dobrikova EY, Florez P, Gromeier M. Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements. Virology311(2), 241–453 (2003).
  • Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl Acad. Sci. USA97(12), 6803–6808 (2000).
  • Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site controlneurovirulence. J. Virol.73(2), 958–964 (1999).
  • Ochiai H, Campbell SA, Archer GE et al. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin. Cancer Res.12(4), 1349–1354 (2006).
  • Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: Radiation-Enhanced Viral Oncolytic Therapy. Int. J. Radiat. Oncol. Biol. Phys.66(3), 637–646 (2006).
  • Fulci G, Breymann L, Gianni D et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA103(34), 12873–12878 (2006).
  • Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol.Ther.12(4), 585–598 (2005).
  • Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy – what have we learned? J. Neurooncol.65(3), 227–236 (2003).
  • Eisenberger A, Elliott BM, Kaufman HL. Viral vaccines for cancer immunotherapy. Hematol. Oncol. Clin. North Am.20(3), 661–687 (2006).
  • Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev.58(8), 931–947 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.